
WD Stock Photos/ Shutterstock.com
Pharmacy chain Boots has launched a medical cannabis prescribing service for people with eligible chronic pain conditions, generalised anxiety disorder or insomnia.
The SureLeaf service, which is led by specialist doctors, will be available to eligible patients aged 25 years and older through the Boots Online Doctor platform.
A spokesperson for Boots UK confirmed to The Pharmaceutical Journal that independent prescribers, including trained pharmacists, will be part of the service.
In an announcement published on 16 November 2026, Boots UK said the service would offer a treatment option where conventional treatments have not provided adequate symptom relief.
Eligible conditions could include generalised anxiety disorder, insomnia disorder, chronic primary and neuropathic pain, fibromyalgia, osteoarthritis and chronic back or neck pain, it said.
The announcement added that before treatment begins, patients must have previously tried conventional treatments without achieving adequate symptom relief and undertake an online assessment, a video consultation with a specialist consultant and a review of the proposed treatment by a multidisciplinary clinical team that includes a second independent consultant.
Once treatment begins, patients will receive ongoing clinical support and monitoring, including an initial review after 28 days, followed by reviews at least every 3 months, it continued.
Mike Barnes, consultant neurologist and founder of the Medical Cannabis Clinicians Society, said: “The law changed eight years ago to allow prescription [of medicinal cannabis] but it’s so far been confined to largely private cannabis clinics around the country, about 40 of them… they’re doing a good job, but I think it makes a big difference to have a large company like Boots involved. It gives it credibility.”
In the UK, medicinal cannabis can be prescribed by, or under the direction of, a doctor who is on the specialist register of the General Medical Council, following a legislative change in 2018 that was promoted by concerns from parents of children with conditions such as severe epilepsy.
A Cochrane review, published in January 2026, found that there was no clear evidence that cannabis-based medicines are a successful treatment for chronic pain.
The results of a meta analysis, published in The Lancet Psychiatry in March 2026, revealed that cannabis-based products for medicinal use (CBPMs) showed no significant effects in the treatment of anxiety.
The Care Quality Commission’s (CQC) annual report on controlled drugs, published in July 2026, highlighted that in 2024, 441,409 CBPMs were prescribed by pharmacists, while 209,644 were prescribed by doctors.
A spokesperson for charity Pain Concern said: “There has been a lot of discussion in the media recently regarding the use of cannabis-based medicinal products (including cannabis oils) in the management of certain health conditions.
“Unfortunately, there is not enough evidence to support the use of this group of drugs in chronic pain management yet, although changes in the law will make research into their uses easier to undertake in the future. Pain Concern calls for further research.”
Private prescribing of CBPMs has been growing rapidly, with 833,525 items prescribed from 1 April 2024 to 31 March 2025, which is more than double the 356,335 items prescribed the previous year, the report noted.
The report also revealed that in 2025, 70 items of cannabidiol were prescribed on the NHS.
In October 2025, the General Pharmaceutical Council (GPhC) carried out a themed review of 25 GPhC-registered pharmacies that were regularly supplying CBPMs.
The review found that most pharmacies were meeting the required standards for the safe procurement, storage and dispensing of CBPMs, but identified a need for stronger collaboration and better information sharing between prescribing clinics, suppliers, pharmacies and other healthcare providers.


